Genentech STARGLO Data Insufficient For Second-Line DLBCL Indication In U.S.

July 18 (Reuters) - ROCHE HOLDING AG ROG.S:

• COLUMVI REMAINS UNDER ACCELERATED APPROVAL FOR THIRD-LINE DLBCL (CORRECTS SOURCE)

• FDA DISCUSSIONS ONGOING FOR SKYGLO STUDY POSTMARKETING REQUIREMENT (CORRECTS SOURCE)

• DATA HAS BEEN SUBMITTED TO OTHER HEALTH AUTHORITIES AROUND WORLD FOR APPROVAL CONSIDERATION (CORRECTS SOURCE)

• GENENTECH PROVIDES UPDATE ON SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR COLUMVI COMBINATION FOR PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

• FDA ISSUES COMPLETE RESPONSE LETTER FOR GENENTECH'S COLUMVI

• STARGLO DATA INSUFFICIENT FOR SECOND-LINE DLBCL INDICATION IN U.S.